argenx stock broadens oral-drug strategy with Unnatural Products deal
Published on 11/11/2026 at 17:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDeal broadens Argenx discovery strategy
- argenx is acquiring the remaining shares of Unnatural Products after holding a minority stake.
- The transaction adds macrocyclic peptide research to Argenx's antibody engineering capabilities.
- Closing is expected by the end of 2026, subject to customary conditions.
argenx agreed on November 9, 2026, to acquire Unnatural Products, adding a macrocyclic peptide discovery platform to its immunology business. The announcement came from argenx in a press release published at 07:00 CET.
argenx already owns a minority stake in the privately held biotechnology company and plans to buy the remaining shares. The companies have worked together for more than two years.
New platform, long-term pipeline option
Unnatural Products brings expertise in macrocyclic peptides, supported by parallel experimentation and machine learning. argenx said the technology complements its antibody engineering and could support potential oral or long-acting medicines for people with serious immune-mediated diseases.
The agreement calls for an upfront payment of 550 million US dollars in cash and up to 595 million US dollars in development and regulatory milestone payments. The potential total consideration is therefore up to 1.15 billion US dollars, but the milestone component depends on future program progress.
Following completion, Unnatural Products' team and leadership are expected to remain in Santa Cruz, California. The site is intended to become argenx's peptide discovery center, while argenx contributes clinical development and commercialization capabilities.
What the move means for investors
The transaction broadens Argenx's technology base beyond its established antibody focus, but the press release does not identify a clinical-stage Unnatural Products candidate or a specific development program. The opportunity therefore depends on research, clinical and regulatory execution rather than an immediate product contribution.
Since the latest report, the Lang & Schwarz quote moved from 868.40 euros at 10:08 CET on Wednesday, November 11, to 877.50 euros at 17:17 CET the same day, a 1.05 percent increase. This is a comparison with the previous report, not a Xetra session comparison.
argenx stock facts
- Company: argenx SE
- ISIN: NL0010832176
- Lang & Schwarz quote: 877.50 euros on Wednesday, November 11, 2026, at 17:17 CET
- Change since latest report: 1.05 percent from 868.40 euros at 10:08 CET
- Transaction: Unnatural Products acquisition for up to 1.15 billion US dollars
The Dutch biotechnology company remains part of the wider AEX market context.
